Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2017 (2017), Article ID 7642049, 6 pages
https://doi.org/10.1155/2017/7642049
Research Article

Changes in Glaucoma Medication during the Past Eight Years and Future Directions in Japan Based on an Insurance Medical Claim Database

Department of Ophthalmology, University of Yamanashi Faculty of Medicine, Chuo, Yamanashi, Japan

Correspondence should be addressed to Kenji Kashiwagi; pj.ca.ihsanamay@kijnek

Received 15 June 2017; Revised 18 August 2017; Accepted 10 September 2017; Published 31 October 2017

Academic Editor: Ciro Costagliola

Copyright © 2017 Masako Sakamoto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Iwase, Y. Suzuki, M. Araie et al., “The prevalence of primary open-angle glaucoma in Japanese: the Tajimi study,” Ophthalmology, vol. 111, no. 9, pp. 1641–1648, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. A. L. Coleman and S. Miglior, “Risk factors for glaucoma onset and progression,” Survey of Ophthalmology, vol. 53, Supplement 1, pp. S3–S10, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. C. Tham, X. Li, T. Y. Wong, H. A. Quigley, T. Aung, and C. Y. Cheng, “Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis,” Ophthalmology, vol. 121, no. 11, pp. 2081–2090, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. D. F. Garway-Heath, D. P. Crabb, C. Bunce et al., “Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial,” Lancet, vol. 385, no. 9975, pp. 1295–1304, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Kashiwagi, “Changes in trend of newly prescribed anti-glaucoma medications in recent nine years in a Japanese local community,” Open Journal of Ophthalmology, vol. 4, pp. 7–11, 2010. View at Publisher · View at Google Scholar
  6. G. M. Richter and A. L. Coleman, “Minimally invasive glaucoma surgery: current status and future prospects,” Clinical Ophthalmology, vol. 10, pp. 189–206, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Nardi, G. Casini, G. Guidi, and M. Figus, “Emerging surgical therapy in the treatment of glaucoma,” Progress in Brain Research, vol. 221, pp. 341–357, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Kimura, T. Sato, S. Ikeda, and M. Noda, “Nakayama T development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage,” Journal of Epidemiology, vol. 20, no. 5, pp. 413–419, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Kashiwagi and T. Furuya, “Persistence with topical glaucoma therapy among newly diagnosed Japanese patients,” Japanese Journal of Ophthalmology, vol. 58, no. 1, pp. 68–74, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. C. E. Bovee and L. R. Pasquale, “Evolving surgical interventions in the treatment of glaucoma,” Seminars in Ophthalmology, vol. 32, no. 1, pp. 91–95, 2017. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Z. Chen and C. C. A. Sng, “Safety and efficacy of microinvasive glaucoma surgery,” Journal of Ophthalmology, vol. 2017, Article ID 3182935, 13 pages, 2017. View at Publisher · View at Google Scholar
  12. T. Krupin, J. M. Liebmann, D. S. Greenfield, R. Ritch, S. Gardiner, and Low-Pressure Glaucoma Study Group, “A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study,” American Journal of Ophthalmology, vol. 151, no. 4, pp. 671–681, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. C. S. Kim, G. J. Seong, N. H. Lee, K. C. Song, and Namil Study Group, Korean Glaucoma Society, “Prevalence of primary open-angle glaucoma in central South Korea the Namil study,” Ophthalmology, vol. 118, no. 6, pp. 1024–1030, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Dandona, R. Dandona, M. Srinivas et al., “Open-angle glaucoma in an urban population in southern India: the Andhra Pradesh eye disease study,” Ophthalmology, vol. 107, no. 9, pp. 1702–1709, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. B. Liang, D. S. Friedman, Q. Zhou et al., “Prevalence of primary open angle glaucoma in a rural adult Chinese population: the Handan eye study,” Investigative Ophthalmology & Visual Science, vol. 52, no. 11, pp. 8250–8257, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Y. Shen, T. Y. Wong, P. J. Foster et al., “The prevalence and types of glaucoma in Malay people: the Singapore Malay eye study,” Investigative Ophthalmology & Visual Science, vol. 49, no. 9, pp. 3846–3851, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Vijaya, R. George, H. Arvind et al., “Prevalence of primary angle-closure disease in an urban south Indian population and comparison with a rural population. The Chennai Glaucoma Study,” Ophthalmology, vol. 115, no. 4, pp. 655–660.e1, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Tanihara, T. Inoue, T. Yamamoto et al., “One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension,” Acta Ophthalmologica, vol. 94, no. 1, pp. e26–e34, 2016. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Tanihara, T. Inoue, T. Yamamoto et al., “Additive intraocular pressure-lowering effects of the rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials,” JAMA Ophthalmology, vol. 133, no. 7, pp. 755–761, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Tanihara, T. Inoue, T. Yamamoto et al., “Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study,” Acta Ophthalmologica, vol. 93, no. 4, pp. e254–e260, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Yamamoto, K. Maruyama, N. Himori et al., “The novel rho kinase (ROCK) inhibitor K-115: a new candidate drug for neuroprotective treatment in glaucoma,” Investigative Ophthalmology & Visual Science, vol. 55, no. 11, pp. 7126–7136, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Djafari, M. R. Lesk, P. J. Harasymowycz, D. Desjardins, and J. Lachaine, “Determinants of adherence to glaucoma medical therapy in a long-term patient population,” Journal of Glaucoma, vol. 18, no. 3, pp. 238–243, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. J. H. Gurwitz, R. J. Glynn, M. Monane et al., “Treatment for glaucoma: adherence by the elderly,” American Journal of Public Health, vol. 83, no. 5, pp. 711–716, 1993. View at Publisher · View at Google Scholar